Podcasts about Menin

In this episode, we took a deep dive intro the landscape of menin inhibitors in AML with Dr. Eytan Stein from MSKCC. Here are the key trials and studies we discussed: ELN 2022 AML Classification https://ashpublications.org/blood/article/140/12/1345/485817/Diagnosis-and-management-of-AML-in-adults-2022Predictors of outcomes in adults with AML and KMT2A rearrangements: https://www.nature.com/articles/s41408-021-00557-6DOT1L inhibitor https://ashpublications.org/blood/article/131/24/2661/37193/The-DOT1L-inhibitor-pinometostat-reduces-H3K79AUGMENT 101: https://ascopubs.org/doi/10.1200/JCO.24.00826Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study: https://ashpublications.org/blood/article/doi/10.1182/blood.2025028357/537139/Menin-inhibition-with-revumenib-for-NPM1-mutatedKOMET-001: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00386-3/abstractSAVE trial: https://ashpublications.org/blood/article/144/Supplement%201/216/530724/Phase-I-II-Study-of-the-All-Oral-Combination-ofKOMET-007: https://library.ehaweb.org/eha/2025/eha2025-congress/4159213/harry.erba.ziftomenib.combined.with.intensive.induction.chemotherapy.2872B329.in.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Ace_id%3D2882%2Aot_id%3D31560%2Amarker%3D5843%2Afeatured%3D19595MEN1 mutations: https://www.nature.com/articles/s41586-023-05755-9 

261. bölümde QNB Dijital Köprü'nün KOBİ'lere yönelik dijital dönüşüm çözümlerini mercek altına alıyoruz. Konuklarım, QNB Dijital Köprü Pazarlama, Ürün ve Marka Yönetimi Bölüm Müdürü Yasemin Akemlek ve Stratejik İş Birlikleri, Müşteri Kazanımı ve Kanal Yönetimi Bölüm Müdürü Gözde Engüzel. (00:00) – Açılış (01:33) – Yasemin Akemlek ve Gözde Engüzel'i tanıyoruz. (03:57) - 20'den fazla dijital çözümün olduğu Dijital Köprü Platformuyla ilgili bu yayında e-Ticaret , e-İhracat ve imalar sektörlerine değineceğiz. KOBİ'lere yönelik son yenilikler neler ve en çok KOBİ'ler hangi hizmetleri istiyor? (05:25) – Üretim tarafında Dijital Köprü neler yapıyor? - Skala Üretim ve Envanter Yönetimi çözümü (09:10) – Üreticilerin bu hizmeti (Skala) kullanırken izledikleri yol nasıl oluyor? Bir üretici bu hizmeti kullanmak istese nerden başlıyorsunuz, nasıl yönlendiriyorsunuz? (11:18) – KOBİ'ler geleneksel yöntemlerle çalışıyorlar, ikna etmek için nasıl ilerliyorsunuz? (12:26) – e- İhracat tarafında platform nasıl bir fayda yaratıyor? (19:30) – Pazaryerlerine ürün yükleme nasıl oluyor? - StockMount e-Ticaret Pazaryeri çözümü (21:30) – Web sitesi alt yapı hazırlamak için nasıl bir yol izleniyor - İkas e-ticaret altyapısı çözümü (22:55) – Pazar yerlerine ek olarak kendi web sitenizden satış yapmak güvenilirlik açısından ne kadar önemli? (25:14) – Yurt dışına nasıl satış yaparım? e- İhracat büyüme rakamları nasıl? Dijital Köprü bu alanda nasıl destek oluyor? Envoyo e-İhracata İlk Adım çözümü (29:37) – Finansal raporların hazırlanması konusunda Dijital Köprü nasıl destek veriyor? Fincheckup Finansal Durum Raporu çözümü Promete finansal danışmanlık çözümü (34:58) – Başarı örnekleri ve geri bildirimler… (36:07) – Son sözler (37:30) – Kitap önerileri Can Dündar – Abim Deniz Dale Carnegie - Dost Kazanma ve İnsanları Kazanma Sanatı (38:50) - Kapanış Sosyal Medya takibi yaptın mı?   Twitter -⁠⁠⁠⁠⁠⁠⁠ https://twitter.com/dunyatrendleri⁠⁠⁠⁠⁠⁠⁠ Instagram -⁠⁠⁠⁠⁠⁠⁠ https://www.instagram.com/dunya.trendleri/⁠⁠⁠⁠⁠⁠⁠ Linkedin -⁠⁠⁠⁠⁠⁠⁠ https://www.linkedin.com/company/dunyatrendleri/⁠⁠⁠⁠⁠⁠⁠ Youtube -⁠⁠⁠⁠⁠⁠⁠ https://www.youtube.com/c/aykutbalcitv⁠⁠⁠⁠⁠⁠⁠ Goodreads - ⁠⁠⁠⁠⁠⁠⁠https://www.goodreads.com/user/show/28342227-aykut-balc⁠⁠⁠⁠⁠⁠⁠   aykut@dunyatrendleri.com Bize bağış yapıp destek olmak için Patreon hesabımız – ⁠⁠⁠⁠⁠⁠⁠https://www.patreon.com/dunyatrendleri⁠⁠⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

In today's episode, we spoke with Naval Daver, MD, about the evolving role of menin inhibition in acute myeloid leukemia (AML) and emerging data with revumenib (Revuforj) presented across ongoing clinical trials. Dr Daver is a professor in the Department of Leukemia and director of the Leukemia Research Alliance Program at The University of Texas MD Anderson Cancer Center in Houston, Texas.

Annalisa Menin"L'Anna che verrà"Giunti Editorewww.giunti.itÈ una torrida sera d'estate quando Anna chiama la sua migliore amica in preda a un attacco di panico. Non è l'ennesima disavventura sentimentale, ma qualcosa di molto più profondo, che ha scosso le fondamenta del suo essere. Adesso, alla soglia dei quarant'anni, Anna è di nuovo sola e terribilmente infelice. Non si riconosce più. Bisognosa di un cambio di prospettiva, decide di prendersi una pausa da tutto e di mollare il caos di New York. Torna nella tranquilla provincia veneta, in un luogo dove il tempo sembra essersi fermato: Casa Bohemia, una romantica stazione ferroviaria in stile anni '30. Tra un corso di giardinaggio e una sessione di filosofia, Anna ricomincia così a mettere insieme i pezzi della sua vita, facendo i conti con il suo passato ma anche con un'idea di futuro che non corrisponde più a ciò che aveva sognato da ragazza. E proprio come un giardino all'inglese, libero eppure controllato, ritroverà nell'imperfetta perfezione della natura un nuovo inizio. Perché non è mai troppo tardi per diventare chi si vuole essere e la relazione con noi stessi è quella più importante della nostra esistenza.Annalisa MeninÈ una scrittrice e imprenditrice esperta di Branding e Comunicazione. Veneziana di nascita, naturalizzata americana, si divide tra New York e l'Europa dal 2006. L'Anna che verrà è il volume conclusivo di un'idea­ le trilogia iniziata con il volume autopub­blicato Il mio ultimo anno a New York (2017) e proseguita con Il Traghettatore (Giunti 2021). Grazie all'iniziativa benefica “Remembe­ring Marco”, supporta giovani studenti italiani in procinto di vivere il Sogno Americano.IL POSTO DELLE PAROLEascoltare fa pensarewww.ilpostodelleparole.itDiventa un supporter di questo podcast: https://www.spreaker.com/podcast/il-posto-delle-parole--1487855/support.

Dr. John Sweetenham and Dr. Erika Hamilton discuss top abstracts that will be presented at the 2025 ASCO Annual Meeting, including research on tech innovations that could shape the future of oncology. Transcript Dr. John Sweetenham: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham, and I'm delighted to be joined today by Dr. Erika Hamilton, a medical oncologist and director of breast cancer and gynecologic cancer research at the Sarah Cannon Research Institute in Nashville, Tennessee. Dr. Hamilton is also the chair of the 2025 ASCO Annual Meeting Scientific Program, and she's here to tell us about some of the key abstracts, hot topics, and novel approaches in cancer care that will be featured at this year's Annual Meeting. Our full disclosures are available in the transcript of this episode. Dr. Hamilton, it's great to have you on the podcast today, and thanks so much for being here. Dr. Erika Hamilton: Thanks, Dr. Sweetenham. I'm glad to be here. Dr. John Sweetenham: Dr. Hamilton, the Presidential Theme of the Annual Meeting this year is ‘Driving Knowledge to Action: Building a Better Future,' and that's reflected in many of the sessions that will focus on action-oriented guidance to improve care for our patients. And as always, there'll be great presentations on practice-changing abstracts that will change treatment paradigms and transform care. Can you tell us about some of the hot topics this year and what you're particularly excited about? Dr. Erika Hamilton: You're right. Dr. Robin Zon's theme is ‘Driving Knowledge to Action: Building a Better Future,' and you're going to see that theme really interlaced throughout the ASCO program this year. We had a record number of submissions. Over 5,000 abstracts will be published, and there'll be about 3,000 presentations, either in oral format or poster presentations. We have 200 dynamic sessions. Many of the discussants will be highlighting key takeaways and how we can translate action-oriented guidance to better treat our patients to build a better future. Our state-of-the-art science will include a Plenary Session. This will feature presentations as well as discussion of each of the presentations for clinical late-breaking abstracts. We have Clinical Science Symposia that I'm particularly excited about this year. These will feature key abstracts as well as discussions and a foundational talk around the subject. We're covering novel antibody-drug conjugate targets, turning “cold” tumors “hot” to include CAR T, as well as the future of cancer detection. There'll be rapid oral abstracts, case-based panels, and this will also feature interactive audience polling and case discussions. I also want to highlight the community connection opportunities. There will be 13 Communities of Practice that will be meeting on-site during ASCO, and there's also really a plethora of networking opportunities for trainees and early-career professionals, a Women's Networking Center, a patient advocate space, and I'm happy to report there will also be live music out on the terrace this year at ASCO. Dr. John Sweetenham: Well, that's going to be a really great addition. I have to say, I think this is always a special time of year because excitement starts to mount as the meeting gets closer and closer. And once the abstracts are out there, I certainly personally feel that the excitement builds. Talking of abstracts, let's dive into some of the key abstracts for this year's meeting. I'd like to start out by asking you about Abstract 505. This reports on 15-year outcomes for women with premenopausal hormone receptor-positive early breast cancer in the SOFT and TEXT trials. It assesses the benefits of adjuvant exemestane and ovarian function suppression or tamoxifen and ovarian function suppression. So, could you talk us through this and tell us what you think the key takeaways from this abstract are? Dr. Erika Hamilton: Absolutely. This is essentially the SOFT and TEXT trials. They are trials that we've been following for quite some time, evidenced by the 15-year outcome. And I think it really answers two very important questions for us regarding adjuvant endocrine therapy for patients that are facing hormone receptor-positive disease. The benefit of ovarian function suppression for one, and then second, the benefit of exemestane over tamoxifen, which is our SERM [selective estrogen receptor modulator]. So, in terms of the SOFT trial, when we talk about distance recurrence-free interval, which I really think is probably the most meaningful because secondary cancers, et cetera, are not really what we're getting at here. But in terms of distant recurrence-free interval, certainly with tamoxifen, using tamoxifen plus ovarian function suppression adds a little bit. But where we really get additional benefits are by moving to exemestane, an aromatase inhibitor with the ovarian function suppression. So, for example, in SOFT, for distant recurrence-free interval for patients that have received prior chemotherapy, the distance recurrence-free interval was 73.5% with tamoxifen, bumped up just a tiny bit to 73.8% with ovarian function suppression. But when we used both ovarian function suppression and switched to that aromatase inhibitor, we're now talking about 77.6%. It may seem like these are small numbers, but when we talk about an absolute benefit of 4%, these are the type of decisions that we decide whether to offer chemotherapy based on. So, really just optimizing endocrine therapy really can provide additional benefits for these patients. Just briefly, when we turn to TEXT, similarly, when we look at distance recurrence-free interval for our patients that are at highest risk and receive chemotherapy, tamoxifen and ovarian function suppression, 79%; 81% with exemestane and ovarian function suppression. And when we talk about our patients that did not receive chemotherapy, it increased from 91.6% up to 94.6%—very similar that 3% to 4% number. So, I think that this is just very important information when counseling our patients about the decisions that they're going to make for themselves in the adjuvant setting and how much we want to optimize endocrine therapy. Dr. John Sweetenham: Thanks so much for your insight into that. Dr. Erika Hamilton: Yeah, absolutely. So, let's turn to hematologic malignancies. Abstract 6506 reports exciting results on the new agent ziftomenib in relapsed/refractory NPM1-mutant acute myeloid leukemia. This is a phase 1b clinical activity study and safety results. This was the pivotal KOMET-001 study. And my question is, will this new agent fulfill an unmet need in this NPM1 space? Dr. John Sweetenham: Yeah, great question. And I think the answer is almost certainly ‘yes'. So, just as some brief background, NPM1 mutation is known to be a driver of leukemogenesis in around 30% of patients with AML, and it's a poor prognostic factor. And typically, about 50% of these patients will relapse within a year of their first-line therapy, and only around 10% of them will get a subsequent complete remission with salvage therapy. Menin inhibitors, which disrupt the interaction between menin and KMT2A, are known to be active in NPM1-mutated as well as in KMT2A-rearranged AML. And ziftomenib is a selective oral menin inhibitor, which in this study was evaluated at a dose of 600 mg once a day, as you mentioned, a phase 1b/2 study, which is multicenter and presented by Dr. Eunice Wang from Roswell Park. It's a relatively large study of 112 patients who were treated with this standard dose with relatively short median follow-up at this time. The median age was 69 years, and median prior therapies were two, but with a range of one to seven. And I think very importantly, 60% of these patients had previously been treated with venetoclax, and 23% of them had had a prior transplant. Looking at the results overall for this study, the overall response rate was 35%, which is actually quite impressive. Specifically for those patients in the phase 2 part of the study, around 23% achieved a CR [complete remission] or CRh [complete remission with partial hematologic recovery]. What's very interesting in my mind is that the response rates were comparable in venetoclax-naive and venetoclax-exposed patients. And the drug was very well tolerated, with only 3% of patients having to discontinue because of treatment-related adverse events. And I think the authors appropriately conclude that, first of all, the phase 2 primary endpoint in the study was met, and that ziftomenib achieved deep and durable responses in relapsed and refractory NPM1-mutated AML, regardless of prior venetoclax, with good tolerance of the drug. And so, I think putting all of this together, undoubtedly, these data do support the potential use of this agent as monotherapy and as a new option for those patients who have relapsed or refractory NPM1-mutated acute myeloid leukemia. So, let's move on a little bit more now and change the subject and change gears completely and talk about circulating tumor DNA [ctDNA]. This has been a hot topic over a number of years now, and at this year's meeting, there are quite a few impactful studies on the use of ctDNA. We have time to focus on just one of these, and I wanted to get your thoughts on Abstract 4503. This is from the NIAGARA trial, which looks at ctDNA in patients with muscle-invasive bladder cancer who receive perioperative durvalumab. Could you tell us a little bit about this study? Dr. Erika Hamilton: So, this was the phase 3 NIAGARA trial, and this is literally looking for patients with muscle-invasive bladder cancer that are cisplatin-eligible, and the addition of durvalumab to neoadjuvant chemotherapy. So here, this is a planned exploratory analysis of ctDNA and the association with clinical outcomes from NIAGARA. So, this is really the type of study that helps us determine which of our patients are more likely to have a good outcome and which of our patients are more likely not to. There were 1,000 randomized patients in this study, and 462 comprised the biomarker-evaluable population. There were about half in the control arm and half in the durvalumab arm. And overall, the ctDNA-positive rate at baseline was about 57%, or a little over half, and that had decreased to about 22% after neoadjuvant treatment. ctDNA clearance rates from baseline to pre-radical cystectomy was about 41% among those with durvalumab and 31% among those in control. And the non-pCR rate was 97% among patients with pre-cystectomy ctDNA-positive status. So, this really gives us some information about predicting who is going to have better outcomes here. We did see a disease-free survival benefit with perioperative durvalumab, and this was observed in post-cystectomy ctDNA-positive as well as the ctDNA-negative groups. Shifting gears now to GI cancer, Abstract 3506 is a long-term safety and efficacy study of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer. And this is the CodeBreaK-101 study. What are your thoughts on this study? Dr. John Sweetenham: Yeah, thanks. A very interesting study, and this abstract builds upon the phase 3 CodeBreaK-300 trial, which I think has just been published in the Journal of Clinical Oncology. This showed that the combination of sotorasib and panitumumab improved clinical outcomes in patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer. The current abstract, as you mentioned, reports the CodeBreaK-101 trial. And this was a phase 1b trial where FOLFIRI therapy was added to sotorasib and panitumumab in previously treated patients with KRAS G12C-mutated metastatic colorectal cancer. The abstract reports the overall and progression-free survival results, as well as some updated safety and response data. So, in this study, patients with this particular mutation who had received at least one prior systemic treatment but were KRAS G12C inhibitor-naive were enrolled into an expansion cohort of the CodeBreaK-101 protocol. And these patients received what apparently now recommended as the standard phase 2 dose of sotorasib of 960 mg daily, plus panitumumab and a standard dose of FOLFIRI. And the primary endpoint of the study was safety, and secondary endpoints included confirmed response, overall response, and progression-free survival, as assessed by the investigator. And by November of last year, 40 patients had been enrolled into this study. Common treatment-related adverse events were cutaneous; some patients developed neutropenia, and stomatitis was fairly widespread. Discontinuation of sotorasib because of adverse events was only seen in 1% of patients, although patients did have to discontinue because of toxicity from some of the other agents in the combination. Looking at the results of this study, the updated objective response rate was 57.5%, and the disease control rate was estimated at 92%, going on 93%, with a median time to response of 1.6 months and a median response duration of 6 months. After a median follow-up of 29.2 months, the median progression-free survival was 8.2 months, and the overall survival 17.9 months. So, the authors have concluded that this combination, including sotorasib, panitumumab, and FOLFIRI, does appear to show quite promising long-term efficacy in pretreated patients with this specific mutation. The ongoing phase 3 study they mentioned, CodeBreaK-301, is aiming to evaluate this combination against the standard of care in the first-line setting for patients with KRAS G12C-mutated colorectal cancer. So, promising results, and we'd be very interested to see how this particular combination performs in the frontline. Dr. Erika Hamilton: Fantastic. Thanks so much for sharing that. Let's shift gears again and really talk about digital technology. I feel that we're all going to have to get much better with this, and really, there are a lot of promises for our patients coming here. There are a lot of abstracts at ASCO that are focusing on innovations in digital technology, including a really interesting psychosocial digital application for caregivers of patients that are undergoing hematopoietic stem cell transplantation. Can you tell us a little bit about this? It's Abstract 11000. Dr. John Sweetenham: Yeah, absolutely. This abstract certainly caught my eye, and I think it's intriguing for a number of reasons, partly because it's app-based, and partly also because it specifically addresses caregiver burden and caregiver needs in the oncology setting, which I think is especially important. And although the context, the clinical context of this study, is hematopoietic stem cell transplantation, I think it has potential applications way beyond that. We all know that caregivers of patients undergoing stem cell transplantation have significant quality-of-life struggles. They are well-documented to have significant psychological and emotional strain before, during, and after stem cell transplantation. And this abstract describes an application called BMT-CARE, which is aimed at improving caregivers' quality of life, caregiver burden, mood symptoms, and coping skills, and so on. So, this was a single-center, randomized trial from MGH [Massachusetts General Hospital] of this app for stem cell transplant caregivers, compared with usual care in those individuals. And the eligible patients, or eligible individuals, were adults caring for patients with heme malignancy undergoing either an autologous or an allogeneic stem cell transplant. Patients were randomly assigned either to use the app or for usual care. And the app itself—and I think it'll be interesting to actually see this at the meeting and visualize it and see how user-friendly and so on it is—but it comprises five modules, which integrate psychoeducation, behavior change, stress management, and they're delivered through a kind of interactive platform of educational games and videos. And then participants were self-reporting at baseline and then 60 days after transplant. So, around 125 patients were enrolled in this study, of around 174 who were initially approached. So, just over 70% uptake from caregivers, which is, I think, relatively high, and evenly distributed between the two randomized arms. And the majority of the participants were spouses. And at 60 days post-stem cell transplant, the intervention participants reported a better quality of life compared with those who received usual care. If you break this down a little bit more, these participants reported lower caregiving burden, lower incidence of depression, fewer PTSD symptoms, and overall better coping skills. So, the authors conclude that this particular app, a digital health intervention, led to pretty substantial improvements in quality of life for these caregivers. So, intriguing. As I said, it'll be particularly interesting to see how this thing looks during the meeting. But if these kind of results can be reproduced, I think this sort of application has potential uses way beyond the stem cell transplant setting. Dr. Erika Hamilton: Yeah, I find that just so fascinating and very needed. I think that the caregiving role is often underestimated in how important that is for the patient and the whole family, and really giving our caregivers more tools in their toolbox certainly is quite helpful. Dr. John Sweetenham: Absolutely. Well, the meeting is getting closer, and as I mentioned earlier, I think anticipation is mounting. And I wanted to say thanks so much to you for chatting with me today about some of the interesting advances in oncology that we're going to see at this year's meeting. There is a great deal more to come. Our listeners can access links to the studies we've discussed today in the transcript of this episode. I'm also looking forward, Dr. Hamilton, to having you back on the podcast after the Annual Meeting to dive into some of the late-breaking abstracts and some of the other key science that's captured the headlines this year. So, thanks once again for joining me today. Dr. Erika Hamilton: Thanks so much for having me. Pleasure. Dr. John Sweetenham: And thank you to our listeners for joining us today. Be sure to catch my “Top Takeaways from ASCO25.” These are short episodes that will drop each day of the meeting at 5:30 p.m. Eastern Time. So, subscribe to the ASCO Daily News Podcast wherever you prefer to listen, and join me for concise analyses of the meeting's key abstracts.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   More on today's speakers: Dr. John Sweetenham   Dr. Erika Hamilton @erikahamilton9   Follow ASCO on social media:  @ASCO on Twitter  ASCO on Bluesky  ASCO on Facebook   ASCO on LinkedIn     Disclosures:     Dr. John Sweetenham:     No relationships to disclose  Dr. Erika Hamilton: Consulting or Advisory Role (Inst): Pfizer, Genentech/Roche, Lilly, Daiichi Sankyo, Mersana, AstraZeneca, Novartis, Ellipses Pharma, Olema Pharmaceuticals, Stemline Therapeutics, Tubulis, Verascity Science, Theratechnologies, Accutar Biotechnology, Entos, Fosun Pharma, Gilead Sciences, Jazz Pharmaceuticals, Medical Pharma Services, Hosun Pharma, Zentalis Pharmaceuticals, Jefferies, Tempus Labs, Arvinas, Circle Pharma, Janssen, Johnson and Johnson   Research Funding (Inst): AstraZeneca, Hutchison MediPharma, OncoMed, MedImmune, Stem CentRx, Genentech/Roche, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix, Novartis, Millenium, TapImmune, Inc., Lilly, Pfizer, Lilly, Pfizer, Tesaro, Boehringer Ingelheim, H3 Biomedicine, Radius Health, Acerta Pharma, Macrogenics, Abbvie, Immunomedics, Fujifilm, eFFECTOR Therapeutics, Merus, Nucana, Regeneron, Leap Therapeutics, Taiho Pharmaceuticals, EMD Serono, Daiichi Sankyo, ArQule, Syros Pharmaceuticals, Clovis Oncology, CytomX Therapeutics, InventisBio, Deciphera, Sermonix Pharmaceuticals, Zenith Epigentics, Arvinas, Harpoon, Black Diamond, Orinove, Molecular Templates, Seattle Genetics, Compugen, GI Therapeutics, Karyopharm Therapeutics, Dana-Farber Cancer Hospital, Shattuck Labs, PharmaMar, Olema Pharmaceuticals, Immunogen, Plexxikon, Amgen, Akesobio Australia, ADC Therapeutics, AtlasMedx, Aravive, Ellipses Pharma, Incyte, MabSpace Biosciences, ORIC Pharmaceuticals, Pieris Pharmaceuticals, Pieris Pharmaceuticals, Pionyr, Repetoire Immune Medicines, Treadwell Therapeutics, Accutar Biotech, Artios, Bliss Biopharmaceutical, Cascadian Therapeutics, Dantari, Duality Biologics, Elucida Oncology, Infinity Pharmaceuticals, Relay Therapeutics, Tolmar, Torque, BeiGene, Context Therapeutics, K-Group Beta, Kind Pharmaceuticals, Loxo Oncology, Oncothyreon, Orum Therapeutics, Prelude Therapeutics, Profound Bio, Cullinan Oncology, Bristol-Myers Squib, Eisai, Fochon Pharmaceuticals, Gilead Sciences, Inspirna, Myriad Genetics, Silverback Therapeutics, Stemline Therapeutics

Aplink Tauragę spiečiasi darbštūs, kūrybingi ir racionalūs svajokliai.Kęstutis Plyskaitis kaldintomis skulptūromis gražina Tauragę ir kraštą. Skalsaus pokalbio užsukime į kalvio dirbtuvę. Apie ką? Meninė kalvystė. Mokymai – šaudymas pistoletu. Savanoriška parama Ukrainos frontui.Vakar vadovas mažmeninėje prekybos įmonėje, šiandien – kvapų kūrėjas ir ne tik... Alius Verumbickas išleido poezijos rinkinį.Norvegiška patirtis perkelta į Eičius? Vidury girios šaknis įleido Eičių bendruomenės Karšuva pirmininkas Simas Gaidelionis su žmona Ieva. Žygeiviams Eičių kaimas tikras atradimas! Jame prasideda Simo kuriamos trasos po Karšuvos girią. Kas mėgsta iššūkius, miške gali apsigyventi kupole. Ieva tikra svajoklė! Susapnavo, kad Eičių vandens bokšte įkurs viešbutį.Ved. Jolanta Jurkūnienė

SINIR ÖTESİ

Send us a textDr. Peter Ordentlich, Ph.D. is Chief Scientific Officer and Founder, Syndax Pharmaceuticals ( https://syndax.com/team/peter-ordentlich-ph-d/ ), a company with a mission to obtain regulatory approval and commercialize drugs that extend and improve the lives of cancer patients, by drawing on the newest scientific research and advances, collaborating with determined problem solvers, and identifying value in overlooked aspects of science.Dr. Ordentlich co-founded the Company in October 2005 and has served as Chief Scientific Officer since September 2016.Dr. Ordentlich previously served as Syndax's Chief Technical Officer, Vice President, Translational Medicine, Executive Director, Translational Science, and Director, Scientific Affairs and Strategic Alliances.Prior to founding the company, Dr. Ordentlich was a scientist at the Salk Institute for Biological Studies, a biological research non-profit organization. He also spent five years as a research scientist at X-Ceptor Therapeutics, Inc., a drug discovery company, which was acquired by Exelixis, Inc.Dr. Ordentlich received a B.A. in Biochemistry and a Ph.D. in Immunology from the University of Pennsylvania.#PeterOrdentlich #SyndaxPharmaceuticals #Oncology #Cancer #Menin #KMT2Ar #AcuteLeukemias #NPM1m #AcuteMyeloidLeukemia #Revuforj #Niktimvo #Axatilimab #Revumenib #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #Podcasting #ViralPodcast #STEM #Innovation #Science #Technology #ResearchSupport the show

Trump'ın yeni ticaret politikasıyla beraber küresel ekonomi ile ilgili yeni tartışmaların alevlendiğini görüyoruz.

Continuing our journeys along the roads which crisscross the landscape of the Western Front, we travel to Flanders in Belgium, and take the old Roman road between the city of Ypres and the town of Menin which follows the story of four years of conflict here in the First World War and discuss once more the 'culture' of The Old Front Line.Got a question about this episode or any others? Drop your question into the Old Front Line Discord Server or email the podcast.Send us a textSupport the show

Newly diagnosed acute myeloid leukemia (AML) is traditionally treated with intensive chemotherapy for eligible patients, but ongoing research is exploring... The post Approaches to optimizing induction therapy in AML: FLT3 inhibitors, menin inhibitors, CPX-351, & more! appeared first on VJHemOnc.

Dans cet épisode du Pod'capsuleur, nous allons découvrir aujourd'hui une brasserie extra souple et qui, malgré une production annuelle de 25 000 hL est qualifiée d' "inefficace" par son propre dirigeant. Elle ne brasse pas une bière mais des centaines, pour des clients disséminés dans le monde entier. Je vous emmène aujourd'hui en Belgique, dans les coulisses d'une brasserie à façon.Rencontre avec Wouter Vermeersch, Belgian Contract Brewery (BCB), à Menin.

Cloud e sanità: problema o opportunità? Cosa significa, in un contesto regolamentato, portare "fuori" i dati? A fronte di quali vantaggi? Quali sono le opportunità di Digital Transformation? Ne parliamo con Saverio Menin, Chief Software Architect di Santagostino.KudosEmanuele Garofalo per la postproduzione dell'episodioContattiTutti i podcast di Improove: https://www.improove.tech/podcastCanale Telegram di Improove: https://t.me/improove_techCanale Telegram di Cloud Champions: https://t.me/CloudChampions

Director Andrew Kightlinger IG@Andrew.vhs and DP Idan Menin IG:@idanmenin talk about their film, from Sylvester Stallone's Balboa Productions, "Lost On a Mountain in Maine" https://www.lostonamountaininmainemovie.com/Matt and Oren go deep about the tough trade-offs they made between budget, VFX, and the need to look realistic. And the guys delve into a wider discussion about the dance between great cinematography and awesome storytelling. Can you shoot on an iPhone and use it alongside an Alexa 35? Would you do it In a commercial, but not in a film and why? And how do you build a relationship between you, as director and your DP that elevates everyone's reel?As always, Oren and Matt get behind the real story to working on a film produced by Sylvester Stallone. Don't miss these juicy details!!---Get a great deal on Magic Mind! https://magicmind.com/shootitjanMatt's Endorsement: Go to a nice movie theater! Oren's Endorsement: Every Frame A Picture's video on YouTube, "Where Do You Put the Camera?" https://youtu.be/wa1O3nqW5hQ?si=ttIU6t8vY0JGhIOeAndrew's Endorsement: "Paradise" on Hulu https://press.hulu.com/shows/paradise/Idan's Endorsement: The liquid emulsion process for creating photographs on a silver-based, liquid photographic emulsion adhered to unconventional surfaces like wood blocks or concrete. Get bonus content on Patreon Hosted on Acast. See acast.com/privacy for more information.

In this podcast, we bring you exclusive updates in acute myeloid leukemia (AML) from the 66th American Society of Hematology... The post Post-ASH AML highlights: novel approaches to frontline therapy, advances with menin inhibitors, & managing FLT3-ITD+ AML appeared first on VJHemOnc.

Yazımızın başlığı edebiyat, hakikat ve gerçek ile bunlara değgin olarak türetilmiş kelimelerin anlamlarına bakmamızı gerektirir. Nev-zuhur bir kelime olan edebiyatın evvelinde edeb, edeb-i kelâm, edebî kelimelerinin bulunduğu, edebiyatın bugünkü tanımının ise 19. yüzyılın ikinci yarısından itibaren oluştuğu bilinen bir husustur.

İyi Ki Podcast'in bu bölümünde "Sorunlarımızı yürüyerek nasıl çözebiliriz?"  bu sorunun peşine düşüyoruz birlilkte. Jean-Jacques Rousseau'dan, Nietzsche'ye, Murakami'den Frederic Gros'a yürümenin yazarlar, filozoflar, düşünürler için yerini irdeliyoruz. Thom Hartmann'ın Walking Your Blues Away kitabından, yürüyerek sorun çözme adımlarının reçetesini de paylaşıyorum bu bölümde sizinle.Bizler düşüncelerimiz değiliz. Bu sebeple düşüncelerimize uzaktan bakmayı ve izleyici konumunda kalabilmeyi öğrenmemiz gerekiyor. Bu bölümde iliklerinize kadar düşüncelerinize uzaktan bakmayı deneyimleyebileceksiniz. Yolunuz hep açık, adımlarınız sonsuz ve farkındalığınız da bol olsun.İyi ki Podcast'in diğer bölümlerini de dinlemek için aşağıdaki linki tıklayabilirsiniz.https://open.spotify.com/playlist/5bHVefMy6JpOCm2sBbGZPP?si=203565b7bccd4d4d&nd=1&dlsi=583a0678adb146c1Benay Durmaz Günerwww.iyikipodcast.cominstagram.com/iyikipodcastDigiHead Media#yürümek #yürümeninfelsefesi #JeanJacquesRousseau #FredericGros #HarukiMurakami  #ThomHartmann #walking #walkingyourbluesaway

✨ Kuntavaalit -podcast: vaalit@puhemedia.fi Leevi ja Rami keskustelevat 612-kulkeesta, Afrikan tähti -pelistä, sukupuoli-identiteestä, sananvapaudesta ja Elon Muskista. Jakso on kuvattu 9.1.2025. ℹ️ LINKIT ASIATON TV: Käytiin Suomen Pahamaineisimmassa Mielenosoituksessa kainaans: Menin suomen rasistisimpaan tapahtumaan. Nuorten arvomaailma: https://yle.fi/a/74-20073201 Meta: More Speech and Fewer Mistakes ⌚ AIKALEIMAT (0:00) Mielipiteet (7:03) 612-soihtukulkue (12:30) Afrikan tähti (18:20) Ennakkoluulot (29:53) Kulttuuri (33:20) Woke (38:46) Arvot (42:12) Sukupuoli (44:52) Identiteetti (49:56) "Mies" (53:31) Zuckerberg (1:00:51) Musk (1:07:58) Antiikin Kreikka (1:12:28) Vaikutusvalta

Scott Menin | The Resolute One by Hope Community Church, Willow Grove

Welcome back to the Oncology Brothers podcast! In this episode, we dive into the highlights from ASH 2024, focusing on key studies in leukemia. Join hosts Drs. Rahul and Rohit Gosain as they discuss groundbreaking research with Dr. Uma Borate from The Ohio State University. Episode Highlights: •⁠  ⁠KOMET 007 Study: An in-depth look at the Phase 1 study on the Menin inhibitor Ziftomenib, exploring its promising results in frontline settings for patients with NPM1 mutations and KMT2A rearrangements. •⁠  ⁠CPX351 vs. 7+3 Induction: A discussion on the liposomal formulation CPX351 and its effectiveness compared to the traditional 7+3 induction therapy, particularly in patients with myelodysplasia-related AML. •⁠  ⁠Venetoclax Combinations: Insights into the use of Venetoclax in combination with various therapies, including its role in treating patients without actionable mutations. Key Takeaways: •⁠  ⁠The importance of NGS testing in identifying targetable mutations in AML. •⁠  ⁠Promising response rates and manageable toxicities associated with Menin inhibitors. •⁠  ⁠The ongoing debate regarding the best induction therapy for AML patients. Don't miss this informative discussion that sheds light on the evolving landscape of leukemia treatment! Subscribe for more updates on oncology topics, including lymphoma, CLL, and myeloma discussions from ASH 2024. Thanks for tuning in! We are the Oncology Brothers. Website: http://www.oncbrothers.com/ X/Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com

#753 - Profetizando obediência para 2025 - Diego Menin by Igreja do Amor

In this episode of the Epigenetics Podcast, we talked with Yadira Soto-Feliciano from MIT about her work on the Menin-MLL complex and the effect of small molecules on its stability in leukemia. We explore the pivotal moments that led her to cancer biology during her graduate studies, where her work included ground-breaking research on the role of the plant homeodomain Finger protein-6 (PHF-6) in leukemia. This work bridged the realms of chromatin accessibility, transcription factors, and cancer cell lineage, providing critical evidence for the concept of lineage plasticity in cancer biology—a topic that has gained significant traction in recent years. Dr. Soto-Feliciano discusses how advances in techniques like CRISPR and ChIP-sequencing have shaped her research, enabling deeper insights into the mechanisms underlying cancer cell identity. As our discussion transitions, Dr. Soto-Feliciano shares her experience in David Allis's lab, illustrating how the collaboration across diverse scientific disciplines enhanced her understanding of chromatin biology and generated significant insights into the mechanics of epigenetic regulation. Highlighting a recent 2023 publication, we unpack her findings related to the conserved molecular switch between MLL1 and MLL3 complexes. These discoveries revealed how the application of small-molecule inhibitors of the menin-MLL interaction can alter gene expression and affect leukemia cells' responses to treatments. We also touch on the operational dynamics within her lab at MIT, established during challenging times marked by the pandemic. Yadira is dedicated to fostering a collaborative and respectful environment among her team, comprised of PhD candidates and research technicians, all sharing a commitment to unraveling the complexities of chromatin regulation. She emphasizes the significance of understanding chromatin scaffold proteins and their role in regulating gene expression and genome organization.   References Soto-Feliciano, Y. M., Bartlebaugh, J. M. E., Liu, Y., Sánchez-Rivera, F. J., Bhutkar, A., Weintraub, A. S., Buenrostro, J. D., Cheng, C. S., Regev, A., Jacks, T. E., Young, R. A., & Hemann, M. T. (2017). PHF6 regulates phenotypic plasticity through chromatin organization within lineage-specific genes. Genes & development, 31(10), 973–989. https://doi.org/10.1101/gad.295857.117 Soto-Feliciano, Y. M., Sánchez-Rivera, F. J., Perner, F., Barrows, D. W., Kastenhuber, E. R., Ho, Y. J., Carroll, T., Xiong, Y., Anand, D., Soshnev, A. A., Gates, L., Beytagh, M. C., Cheon, D., Gu, S., Liu, X. S., Krivtsov, A. V., Meneses, M., de Stanchina, E., Stone, R. M., Armstrong, S. A., … Allis, C. D. (2023). A Molecular Switch between Mammalian MLL Complexes Dictates Response to Menin-MLL Inhibition. Cancer discovery, 13(1), 146–169. https://doi.org/10.1158/2159-8290.CD-22-0416 Zhu, C., Soto-Feliciano, Y. M., Morris, J. P., Huang, C. H., Koche, R. P., Ho, Y. J., Banito, A., Chen, C. W., Shroff, A., Tian, S., Livshits, G., Chen, C. C., Fennell, M., Armstrong, S. A., Allis, C. D., Tschaharganeh, D. F., & Lowe, S. W. (2023). MLL3 regulates the CDKN2A tumor suppressor locus in liver cancer. eLife, 12, e80854. https://doi.org/10.7554/eLife.80854   Related Episodes MLL Proteins in Mixed-Lineage Leukemia (Yali Dou) Targeting COMPASS to Cure Childhood Leukemia (Ali Shilatifard)   Contact Epigenetics Podcast on Instagram Epigenetics Podcast on Mastodon Epigenetics Podcast on Bluesky Dr. Stefan Dillinger on LinkedIn Active Motif on LinkedIn Active Motif on Bluesky Email: podcast@activemotif.com

Welcome to the show this week.  Our guest is cinematographer Idan Menin who is on to talk about his latest work on the film Lost on a Mountain in Maine. The film looks great and Idan has a ton of stories to share from pre-production all the way through to his work on set.  I really […] The post The Wandering DP Podcast: Episode #461 – Idan Menin appeared first on Cinematography Podcast & Tutorials.

Modern Wisdom Key Takeaways  Now more than ever,young men are uncertain about what the world needs from themThe increase in young male suicide may be due to men retreating from the difficulties and challenges of modern society “The state of feeling unneeded is literally fatal.” – Richard Reeves Four out of five teens who commit suicide are boys: Across every age group, the suicide rate is 4x higher amongst men than women There has been an expansion in the domains of neediness for women and a contraction in the domain of neediness for men The mental health field is more female-friendly than male-friendly; the whole field of mental health has been coded as female and feminine – and we wonder why men are not interested in it!  Young men feel politically homeless, and they especially do not feel welcomed by the political left; instead of turning to the left or the right, younger men tend to retreat Recently, there has been a massive increase in drug poisoning deaths among young men From 2001 to today in the United States, the increase in deaths from drug poisoning is equivalent to an additional 400,000 menIn the US, only half of men in their 30s and 40s without a college degree are in a household with childrenFor men, the old form of neediness as a protector has been significantly evacuated and replaced by nothing The best protector against despair is realizing that the world needs you Read the full notes @ podcastnotes.orgRichard Reeves is a writer, researcher and the Founder of the American Institute for Boys & Men. Men have been struggling for a long time. What exactly is going on? What resources can genuinely help modern men, and how can we better understand the dynamics that are driving this decline in male wellbeing. Expect to learn why Obama endorsed Richard's book, the scary trends about male suicide, why it's important for humans to feel needed, whether the Harris-Walz campaign has even considered men's existence, if this upcoming election will be decided by masculinity, Richard's thoughts on therapy for men and much more…. Sponsors: See discounts for all the products I use and recommend: https://chriswillx.com/deals Get 50% off your first Factor Meals box at https://factormeals.com/MW50 (automatically applied at checkout) Get expert bloodwork analysis and bypass Function's 300,000-person waitlist at https://functionhealth.com/modernwisdom (automatically applied at checkout) Get a 20% discount on your first order from Maui Nui Venison by going to https://mauinuivenison.com/modernwisdom (use code MODERNWISDOM) Get a 20% discount on the best supplements from Momentous at https://livemomentous.com/modernwisdom (automatically applied at checkout) Extra Stuff: Get my free reading list of 100 books to read before you die: https://chriswillx.com/books Try my productivity energy drink Neutonic: https://neutonic.com/modernwisdom Episodes You Might Enjoy: #577 - David Goggins - This Is How To Master Your Life: https://tinyurl.com/43hv6y59 #712 - Dr Jordan Peterson - How To Destroy Your Negative Beliefs: https://tinyurl.com/2rtz7avf #700 - Dr Andrew Huberman - The Secret Tools To Hack Your Brain: https://tinyurl.com/3ccn5vkp - Get In Touch: Instagram: https://www.instagram.com/chriswillx Twitter: https://www.twitter.com/chriswillx YouTube: https://www.youtube.com/modernwisdompodcast Email: https://chriswillx.com/contact - Learn more about your ad choices. Visit megaphone.fm/adchoices

Menin inhibitors are emerging as a promising therapeutic approach in acute myeloid leukemia (AML), particularly in patients with specific genetic... The post An update on menin inhibition in AML from iwAL 2024: current data, mechanisms of resistance, & more! appeared first on VJHemOnc.

Politi-Cast'te bu hafta gazeteciler Sedat Bozkurt ve Berna Can Türkiye gündeminin öne çıkan başlıklarını ele aldı. Yenidoğan Çetesi ile ilgili yaşanan olaylar ve tepkiler, toplumsal çürümenin ve ülke yönetimindeki eksikliklerin nasıl derinleştiğini gözler önüne serdi. Berna Can ve Sedat Bozkurt, olayların perde arkası ve Türkiye'nin sosyal, ekonomik ve siyasi yapısı üzerine konuştu. Learn more about your ad choices. Visit megaphone.fm/adchoices

Namaz, dinin direği ve imanın ikiz kardeşi. Peki sizce gerçekten namazlarımıza yeterli hassasiyeti gösterebiliyor muyuz? Bu bölümde, namazın önemini ve namazda derinleşme yollarını ayet ve hadislerden örneklerle anlatmaya çalıştık. İstifadeye medar olması ümidiyle... 00:00 İmandan Sonraki En Önemli Mesele: Namaz 00:57 Namazla İlgili Üç Önemli Kavram 05:30 Namazımızı Nasıl Daha Kaliteli Hâle Getirebiliriz? 07:21 Namaza İlk Hazırlık: Abdest 10:28 Namaza Davet: Ezan 13:04 Farz Namazın Başlamak Üzere Olduğunu Haber Veren Çağrı: Kamet 14:50 Gayba Ait Bir İş: Niyet Kurantime projemize destek olmak isterseniz buyrun: https://www.gofundme.com/f/kuran-time...

„Meninė dokumentika daugiau stebi ir palieka klausimus žiūrovams patiems surasti savo santykį su tuo, kas vyksta su mūsų planeta, kaip ji keičiasi ir kaip ją keičia mūsų veikla“, – sako Ona Kotryna Dikavičiūtė, viena iš šių metų Vilniaus dokumentinių filmų festivalio programos kuratorių.Šiemet šiame festivalyje ne vienas filmas savaip prisiliečia prie gamtos, aplinkosaugos, aktyvizmo ir ekologinės taršos temų. Tarp jų – režisierės Laurence Lévesque juosta „Okurimono“ (jap. „Dovana“), tyrinėjanti tylą, kuri tebekausto 1945 m. Nagasakio ant numestos atominės bombos sprogimą išgyvenusių žmonių prisiminimus.Viena iš trumpametražių filmų programų – „Susitelkimas“ žvelgia į pavienes ir bendras žmonių pastangas išgyventi pokyčius ekologinės krizės akivaizdoje. O programa „Intervencija“ siūlo atkreipti dėmesį į kolonializmo žaizdas kraštovaizdžiuose, taip pat ir ekologiniuose.Tuo metu režisierių Beno Russelo ir Guillaumo Cailleau „Tiesioginis metodas“ kviečia beveik 4 valandas praleisti su įvairiais prancūzų aktyvistais, kurie valdžios laikomi „ekoteroristais“.Kaip ir kokias aplinkosaugos temas renkasi tyrinėti dokumentinio kino autoriai ir kodėl jiems tai svarbu?Autorė Vaida Pilibaitytė

Teknoloji ve makineleşmenin hayatımızı nasıl şekillendireceği üzerine kafa yorarken, robotlarla iletişimden insan-robot evliliklerine kadar geniş bir perspektifte ilginç sorulara yanıt arıyoruz.

In this week's episode we'll discuss how CD8+ T-cell differentiation and dysfunction inform treatment response in acute myeloid leukemia; learn more about the effect of ATM germline pathogenic variants on the outcomes in children with ataxia-telangiectasia and hematological malignancies; and discuss the preclinical efficacy of a potent, selective menin-KMT2A inhibitor JNJ-75276617 in KMT2A- and NPM1-altered leukemias.Featured Articles:CD8+ T-cell differentiation and dysfunction inform treatment response in acute myeloid leukemiaATM germ line pathogenic variants affect outcomes in children with ataxia-telangiectasia and hematologicalmalignanciesPreclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) inKMT2A- and NPM1-altered leukemias

No episódio, Rodrigo Capelo entrevista Rubens Menin, CEO da SAF do Atlético Mineiro, junto com Laura Rezende, André Ribas e Pedro Spinelli. O mandatário conta sobre os desafios de administrar uma SAF do clube do coração, quais planos vislumbra para o crescimento do Galo e de sua torcida em todo o país e sobre a possibilidade de formação de uma liga unificada. Menin ainda fala sobre a rivalidade com Alexandre Kalil e refuta a possibilidade de se tornar político.

Why are pigs roaming up and down the rows of more and more vineyards? Do biodynamic preparations really help vineyards by treating them more holistically or is this junk science? How does fog help vineyards, especially in Napa and Sonoma? In this episode of the Unreserved Wine Talk podcast, I'm chatting with author Sophie Menin. You can find the wines we discussed at https://www.nataliemaclean.com/winepicks   Giveaway Three of you will win a copy of Sophie Menin and Bob Chaplin's terrific new book A Year In The Vineyard. To qualify, all you have to do is email me at natalie@nataliemaclean.com and let me know that you've posted a review of the podcast. I'll choose three people randomly from those who contact me.  Good luck!   Highlights What does “fixing nitrogen” mean, and why is it important for vines? Do biodynamic preparations help vineyards by treating them more holistically? How does the moon's gravitational pull influence the ideal time for pruning vines? Why are shoot thinning and winter pruning necessary for improving vine architecture? How have bats, pigs, and sheep become essential additions to many vineyards? Why did one winery decide to plant vines in concentric circles rather than the traditional rows? How does light influence wine production? What are "crystalline cathedrals," and how do they help to protect buds in sub-zero weather? What methods are vineyards using to warm the air and combat potential damage from frost? How does fog help vineyards, especially in Napa and Sonoma? In the Museum of Sophie Menin, what three objects would be in the central display? Which wine would Sophie pair with her favourite childhood food, carrot cake? What are Sophie's favourite wine gadgets? Which bottle of wine would Sophie Menin want to share with Alice Waters?   About Sophie Menin Sophie Menin is an author and journalist who has contributed to several top publications such as The New York Times, Wine Spectator, and more. Her wine writing focuses on the myriad ways that wine connects us with our senses and the rhythms of the natural world.   Bonus Interview - Ottawa Independent Writers | Writer's Workshop: Highlights The five steps to tasting wine What makes a good wine versus a mediocre wine? Memoir mistake #1: Assuming that your story is the focus of the book. This is especially important if you're planning to write your own story someday, whether it's for broad publication or just for friends and family as a legacy.   About Ottawa Independent Writers Ottawa Independent Writers (OIW) was formed in 1986 as a venue for people with a passion for creating fiction and non-fiction, for writing poetry and plays, and for stringing words together in a variety of other formats. OIW's members are involved in every aspect of the printed and electronic word.         To learn more, visit https://www.nataliemaclean.com/294.

Qual o futuro do futebol brasileiro na visão do maior acionista do Atlético? Clube será uma fábrica de Hulks? Qual o prazo para zerar a dívida do Galo? De onde vem a rusga com Kalil? Com André Ribas, Laura Rezende, Pedro Spinelli e Rodrigo Capelo

Why do many wineries plant roses at the end of each vine row? What does bee activity tell you about a vineyard? What does it mean for winemakers to have an "aesthetic vision"? In this episode of the Unreserved Wine Talk podcast, I'm chatting with author Sophie Menin. You can find the wines we discussed at https://www.nataliemaclean.com/winepicks   Giveaway Three of you will win a copy of Sophie Menin and Bob Chaplin's terrific new book A Year In The Vineyard. To qualify, all you have to do is email me at natalie@nataliemaclean.com and let me know that you've posted a review of the podcast. I'll choose one person randomly from those who contact me.  Good luck!   Highlights What was the exact moment Sophie decided she wanted to become a writer? What were the best and worst moments of Sophie's writing career? Why would Sophie want to be a teacher if she didn't pursue writing professionally? What was the inspiration behind writing A Year In The Vineyard? Which moments were most memorable from Sophie's experience with the Olivier Leflaive vineyard? How did Sophie's collaboration with Bob Chaplin make A Year In The Vineyard different from other books on similar topics? How did Sophie choose which wineries to feature in A Year In The Vineyard? What was the most surprising thing Sophie discovered while researching the book? How are some wineries changing the way they treat vineyard workers? What was the most impactful feedback Sophie received on the book? What were some of the challenges of writing A Year In The Vineyard? How was the visual storytelling developed? Which emerging trends in vineyard practices did Sophie observe in her research? Why is natural resilience important in vineyards? How did Sophie convince Hugh Johnson to write the foreword? Why does Sophie consider vineyards to be gardens? What does it mean for winemakers to hold an "aesthetic vision"? Why is it important to live close to the earth? What's behind the recent practice of wineries planting roses at the end of each vineyard row? Why is biodiversity important to vine health?   Key Takeaways Why do many wineries plant roses at the end of each vine row? Anything that could negatively impact the vineyard, such as mildew or pests, will affect roses first. The roses are like that proverbial canary in the coal mine. What does bee activity tell you about a vineyard? Well-cared-for vineyards begin to look like English gardens or even the Biblical Eden because they're not only full of flowers and other plants, but they also have lots of bee activity. It's a measure of their health and biodiversity. What does it mean for winemakers to have an "aesthetic vision"? Every choice winemakers take considers what kind of wine they want to make.   About Sophie Menin Sophie Menin is an author and journalist who has contributed to several top publications such as The New York Times, Wine Spectator, and more. Her wine writing focuses on the myriad ways that wine connects us with our senses and the rhythms of the natural world.         To learn more, visit https://www.nataliemaclean.com/293.

#beşerimünasebetler ⁉️ Bu yıl tarihin en yoğun seçim yılı. 70'den fazla ülkede seçim yapıldı, yapılacak. Ancak araştırmalara göre seçmenler, partilerin kampanyasını izlemiyor, fikrini söylemiyor. Neden? Prof.Dr. Nezih Orhon'dan dinleyin.

Dr. Mollie Leoni, Executive Vice President for Clinical Development of Kura Oncology, discusses the company's ziftomenib program, a menin inhibitor for acute myeloid leukemia (AML). The company initially allowed all AML patients to participate in the clinical study, but later found that specific subtypes, such as those with NPM1 mutation or KMT2A rearrangement, were more likely to respond to the menin inhibitor. They also discovered other subtypes that were responsive, expanding the potential patient population. Understanding the role of menin and menin inhibitors in addressing abnormal gene expression and promoting healthy cell development opens the door to potential combination therapy, where menin inhibitors could be layered onto existing treatments for various cancers related to menin independence. Mollie explains, "In oncology, we have gotten good at treating the end state, but cancer has many, many causes with a common final endpoint to the way the cells look. So, it's many, many different diseases all at once. We've learned and are learning that with better technology and a better understanding of cancer in general we can identify not just how to stop the end state but how to stop it from starting." "That's where ziftomenib comes in. Ziftomenib addresses key mutations that when they occur, are what cause the development of cancer. So you're able to shut down the development and force the cells to develop normally rather than waiting until they're already diseased and killing them with chemotherapy or some other cytotoxic agent." "There is a protein complex that we refer to as the menin MLL complex, which goes rogue when something unusual happens in the cell. For example, that could be an NPM1 mutation. That could be a KMT2A rearrangement. Those are two things that are well-known to happen within AML diseases. It could also be a SETD2 RUNX1 mutation. So many types of mutations could happen that could cause this machinery to go rogue within the cell. And that complex causes genes to become active at levels and at times that are abnormal." #KuraOncology #Ziftomenib #MeninInhibitors #PrecisionMedicine #BTD #AML KuraOncology.com Listen to the podcast here

Dr. Mollie Leoni, Executive Vice President for Clinical Development of Kura Oncology, discusses the company's ziftomenib program, a menin inhibitor for acute myeloid leukemia (AML). The company initially allowed all AML patients to participate in the clinical study, but later found that specific subtypes, such as those with NPM1 mutation or KMT2A rearrangement, were more likely to respond to the menin inhibitor. They also discovered other subtypes that were responsive, expanding the potential patient population. Understanding the role of menin and menin inhibitors in addressing abnormal gene expression and promoting healthy cell development opens the door to potential combination therapy, where menin inhibitors could be layered onto existing treatments for various cancers related to menin independence. Mollie explains, "In oncology, we have gotten good at treating the end state, but cancer has many, many causes with a common final endpoint to the way the cells look. So, it's many, many different diseases all at once. We've learned and are learning that with better technology and a better understanding of cancer in general we can identify not just how to stop the end state but how to stop it from starting." "That's where ziftomenib comes in. Ziftomenib addresses key mutations that when they occur, are what cause the development of cancer. So you're able to shut down the development and force the cells to develop normally rather than waiting until they're already diseased and killing them with chemotherapy or some other cytotoxic agent." "There is a protein complex that we refer to as the menin MLL complex, which goes rogue when something unusual happens in the cell. For example, that could be an NPM1 mutation. That could be a KMT2A rearrangement. Those are two things that are well-known to happen within AML diseases. It could also be a SETD2 RUNX1 mutation. So many types of mutations could happen that could cause this machinery to go rogue within the cell. And that complex causes genes to become active at levels and at times that are abnormal." #KuraOncology #Ziftomenib #MeninInhibitors #PrecisionMedicine #BTD #AML KuraOncology.com Download the transcript here

A different edition of the ‘Matt Talks Wine & Stuff with Interesting People' Podcast! My guest is Sophie Menin an award-winning wine writer and the author of, ‘A Year in the Vineyard'. Her book is packed with 180 gorgeous pictures from the world's most stunning wine regions. From Piedmont to Burgundy to Napa and everywhere in between.  We discuss the many years of work that went into her latest work that will give you a completely different perspective of what it takes to make a bottle of wine.

Neden öpüşüyoruz?Ne zamandır öpüşüyoruz?Sadece biz mi? Bonobolar ve şempanzeler de öpüşüyor. Peki ama niçin?Yeni bir araştırmayla öpüşmenin tarihi bin yıl geriye gitti.Tam 4500 yıldır kayıtlı ve belgeli şekilde sevgililerimizin dudaklarına romantik öpücükler konduruyoruz.Yahuda bile Hz. İsa'yı bir öpücükle çarmıha gönderdi.Öpüşmenin 100 bin yıllık tarihi bu bölümde...İyi dinlemeler...Yeni Haller sizlerin desteğiyle yayına devam eden bir podcast kanalı.Bölümlerin daha sık yayınlanması, Yeni Haller'in yayın hayatının uzun olması için siz de aşağıdaki linklerden destek olabilirsiniz.Patreon'a özel bölümleri dinlemek, bölümlere herkesten 24 saat önce erişmek ve Yeni Halller'e destek olmak için:www.patreon.com/yenihallerYeni Haller'in bir de Buy Me A Coffee hesabı var artık. Buradan destek olmak çoook daha kolay. Patreon'da sorun yaşayanlar için açtım efendim. Buyurun:https://www.buymeacoffee.com/yenihallerEray Özer'e ulaşmak için:https://www.instagram.com/eray_ozerhttps://twitter.com/ErayOzeryenihallerpodcast@gmail.com

Sophie Menin is a journalist, Editor, and Author, living and working in NYC. With a Masters Degree in Cultural Reporting and Criticism from NYU, a professional degree in the Culinary Arts from the Institute of Culinary Education and an advanced WSET certificate, Sophie is an award-winning writer focusing on how wine connects us with our sense and the rhythms of the natural world. She has written for the NY Times, Wine Spectator, Barron's, Saveur and Punch, to name a few. Sophie's new book “A Year in the Vineyard” offers an insider's look into the yearlong cycle of the vine. The book is on sale June 4th.  Heritage Radio Network is a listener supported nonprofit podcast network. Support The Grape Nation by becoming a member!The Grape Nation is Powered by Simplecast.

Sophie Menin is an award-winning cultural journalist and author whose work has appeared in The New York Times, Barron's, Wine Spectator, and Saveur. She earned an MA in Cultural Reporting and Criticism from the Arthur L. Carter Journalism Institute at New York University, and a professional degree in the Culinary Arts from the Institute of Culinary Education. Her wine writing focuses on the myriad ways that wine connects us with our senses and the rhythms of the natural world. She has just co-authored a book, A Year in the Vineyard, with environmental artist Bob Chaplin. It beautifully captures the yearlong cycle of the vine, framed in the context of the ongoing evolution of viticulture as climate change reshapes centuries of tradition. A Year in the Vineyard will be released on June 4.

Günaydın! Cuma sabahından herkese merhaba. Medyascope'un podcast'i Güne Başlarken'de günün öne çıkan haberlerine birlikte bakalım.

Following the 2011 wave of revolutions and protests in North Africa and the Middle East, new discussions of individual freedoms emerged in the Moroccan public sphere and human rights discourse. A segment of the public rallied around the removal of an article in the penal code that punished sexual relationships outside of marriage. As debates about personal and sexual freedom gain momentum, love and intimacy remain complex issues.  Moving between public, clandestine, and online interactions, Quest for Love in Central Morocco: Young Women and the Dynamics of Intimate Lives (Syracuse University Press, 2024) explores the creative ways young women navigate desire and morality. Laura Menin's ethnography focuses on young women living in the low-income and lower-middle-class neighbourhoods of a midsized town in Central Morocco, far from the overt influence of city life. At the heart of the book, Menin draws upon ideas of "love" as an ethnographic object and source of theoretical examination. She demonstrates that love, as a complex cultural and historical phenomenon shaped through intersecting socioeconomic and political developments, is crucial in thinking through generational changes and debates in Morocco and the Middle East more broadly. What is at stake in the quest for love, she argues, is not only the making of gendered selves and intimate relationships, but also the imagination of social and political life. Rituparna Patgiri has a PhD in Sociology from Jawaharlal Nehru University (JNU), New Delhi. Her research interests lie in the areas of food, media, gender and public. She is also one of the co-founders of Doing Sociology. Patgiri can be reached at @Rituparna37 on Twitter. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

Following the 2011 wave of revolutions and protests in North Africa and the Middle East, new discussions of individual freedoms emerged in the Moroccan public sphere and human rights discourse. A segment of the public rallied around the removal of an article in the penal code that punished sexual relationships outside of marriage. As debates about personal and sexual freedom gain momentum, love and intimacy remain complex issues.  Moving between public, clandestine, and online interactions, Quest for Love in Central Morocco: Young Women and the Dynamics of Intimate Lives (Syracuse University Press, 2024) explores the creative ways young women navigate desire and morality. Laura Menin's ethnography focuses on young women living in the low-income and lower-middle-class neighbourhoods of a midsized town in Central Morocco, far from the overt influence of city life. At the heart of the book, Menin draws upon ideas of "love" as an ethnographic object and source of theoretical examination. She demonstrates that love, as a complex cultural and historical phenomenon shaped through intersecting socioeconomic and political developments, is crucial in thinking through generational changes and debates in Morocco and the Middle East more broadly. What is at stake in the quest for love, she argues, is not only the making of gendered selves and intimate relationships, but also the imagination of social and political life. Rituparna Patgiri has a PhD in Sociology from Jawaharlal Nehru University (JNU), New Delhi. Her research interests lie in the areas of food, media, gender and public. She is also one of the co-founders of Doing Sociology. Patgiri can be reached at @Rituparna37 on Twitter. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/gender-studies

Following the 2011 wave of revolutions and protests in North Africa and the Middle East, new discussions of individual freedoms emerged in the Moroccan public sphere and human rights discourse. A segment of the public rallied around the removal of an article in the penal code that punished sexual relationships outside of marriage. As debates about personal and sexual freedom gain momentum, love and intimacy remain complex issues.  Moving between public, clandestine, and online interactions, Quest for Love in Central Morocco: Young Women and the Dynamics of Intimate Lives (Syracuse University Press, 2024) explores the creative ways young women navigate desire and morality. Laura Menin's ethnography focuses on young women living in the low-income and lower-middle-class neighbourhoods of a midsized town in Central Morocco, far from the overt influence of city life. At the heart of the book, Menin draws upon ideas of "love" as an ethnographic object and source of theoretical examination. She demonstrates that love, as a complex cultural and historical phenomenon shaped through intersecting socioeconomic and political developments, is crucial in thinking through generational changes and debates in Morocco and the Middle East more broadly. What is at stake in the quest for love, she argues, is not only the making of gendered selves and intimate relationships, but also the imagination of social and political life. Rituparna Patgiri has a PhD in Sociology from Jawaharlal Nehru University (JNU), New Delhi. Her research interests lie in the areas of food, media, gender and public. She is also one of the co-founders of Doing Sociology. Patgiri can be reached at @Rituparna37 on Twitter. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/middle-eastern-studies

Following the 2011 wave of revolutions and protests in North Africa and the Middle East, new discussions of individual freedoms emerged in the Moroccan public sphere and human rights discourse. A segment of the public rallied around the removal of an article in the penal code that punished sexual relationships outside of marriage. As debates about personal and sexual freedom gain momentum, love and intimacy remain complex issues.  Moving between public, clandestine, and online interactions, Quest for Love in Central Morocco: Young Women and the Dynamics of Intimate Lives (Syracuse University Press, 2024) explores the creative ways young women navigate desire and morality. Laura Menin's ethnography focuses on young women living in the low-income and lower-middle-class neighbourhoods of a midsized town in Central Morocco, far from the overt influence of city life. At the heart of the book, Menin draws upon ideas of "love" as an ethnographic object and source of theoretical examination. She demonstrates that love, as a complex cultural and historical phenomenon shaped through intersecting socioeconomic and political developments, is crucial in thinking through generational changes and debates in Morocco and the Middle East more broadly. What is at stake in the quest for love, she argues, is not only the making of gendered selves and intimate relationships, but also the imagination of social and political life. Rituparna Patgiri has a PhD in Sociology from Jawaharlal Nehru University (JNU), New Delhi. Her research interests lie in the areas of food, media, gender and public. She is also one of the co-founders of Doing Sociology. Patgiri can be reached at @Rituparna37 on Twitter. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/anthropology

Following the 2011 wave of revolutions and protests in North Africa and the Middle East, new discussions of individual freedoms emerged in the Moroccan public sphere and human rights discourse. A segment of the public rallied around the removal of an article in the penal code that punished sexual relationships outside of marriage. As debates about personal and sexual freedom gain momentum, love and intimacy remain complex issues.  Moving between public, clandestine, and online interactions, Quest for Love in Central Morocco: Young Women and the Dynamics of Intimate Lives (Syracuse University Press, 2024) explores the creative ways young women navigate desire and morality. Laura Menin's ethnography focuses on young women living in the low-income and lower-middle-class neighbourhoods of a midsized town in Central Morocco, far from the overt influence of city life. At the heart of the book, Menin draws upon ideas of "love" as an ethnographic object and source of theoretical examination. She demonstrates that love, as a complex cultural and historical phenomenon shaped through intersecting socioeconomic and political developments, is crucial in thinking through generational changes and debates in Morocco and the Middle East more broadly. What is at stake in the quest for love, she argues, is not only the making of gendered selves and intimate relationships, but also the imagination of social and political life. Rituparna Patgiri has a PhD in Sociology from Jawaharlal Nehru University (JNU), New Delhi. Her research interests lie in the areas of food, media, gender and public. She is also one of the co-founders of Doing Sociology. Patgiri can be reached at @Rituparna37 on Twitter. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/sociology

Bu bölüm biraz 38. bölümün devamı niteliğinde. Yani sağlıklı benliğimizi yeme bozukluğu benliğimizden ayırdıktan iyileşmeye kadar geçen 7 aşamalı yolculuğu konuşuyoruz. Instagram @antidietfoody Email iremwlazlo@gmail.com Websayfam www.iremwlazlo.com

HelloWelcome to Life Points with Ronda, the podcast that helps you navigate life's challenges with practical wisdom and actionable advice. where we discuss important topics that affect our everyday lives. Today, I'm speaking to the Gentleman and Gentleman our topic for today is : Nourishing the Mind: The Role of Proper Nutrition in Supporting Mental Clarity for MenIn today's fast-paced world, mental health has emerged as a significant concern affecting individuals of all genders. While seeking professional help remains crucial, adopting a holistic approach to mental well-being can amplify the effects of therapy. This blog aims to shed light on the importance of mental clarity and how consuming the right foods can aid in the fight against mental illness, specifically tailored for gentlemen.--- Send in a voice message: https://podcasters.spotify.com/pod/show/dailylifetip/messageSupport the showhttps://chat.openai.com/g/g-8E47AuJfB-life-points-assistanthttps://FaceBook.com/Lifepointswithronda1https://youtube.com/@lifepointswithronda2968https://TikTok.com/@lifepointswithrondahttps://Instagram.com/@lifepointswithrondahttps://Patreon.com/@lifepointswithrondahttps://Lifepointswithronda.com